Authority is built by explaining the inconvenient studies as carefully as the favourable ones. Omega-3 for dry eye is a good example: credible trials point in different directions.

This article separates product-specific evidence from broad omega-3 evidence and explains why study design, oil form, placebo choice and dry-eye subtype can change the answer.

The 2016 PRN-formula trial: positive results

Epitropoulos and colleagues randomized 105 adults with dry eye and meibomian gland dysfunction to four daily softgels providing 1,680 mg EPA and 560 mg DHA in rTG form, or safflower-oil control, for 12 weeks. The active group showed greater improvement in tear osmolarity, tear break-up time, OSDI symptom scores and MMP-9.

This study matters because the EPA:DHA amounts and rTG form closely match PRN De3. It also aligns with the outcomes named in Health Canada's licence. Limitations include modest size, 12-week duration, and author disclosures involving the product company.

The DREAM trial: no advantage over placebo

The 2018 DREAM trial enrolled 535 people at 27 sites. Participants received 2,000 mg EPA plus 1,000 mg DHA in ethyl ester form or an olive-oil placebo. After one year, both groups improved, but omega-3 was not significantly better for symptoms or common clinical signs.

DREAM is larger and highly influential. It should prevent categorical statements that “omega-3 is proven to treat dry eye.” It did not test PRN De3's precise ratio, rTG form or vitamin D3, but it did test a substantial marine omega-3 dose in typical moderate-to-severe dry eye.

The 2024 De3 trial: a formula-specific negative result

A 2024 randomized clinical trial focused on dry eye associated with meibomian gland dysfunction. The omega-3 group received De3 at 1,680 mg EPA and 560 mg DHA daily; the control group received 3,000 mg grapeseed oil. Fewer than 60 participants were evaluated per group, and the study did not show a symptom benefit for De3 over control at 12 weeks.

This study is especially relevant because it used the branded formula. It does not erase the 2016 findings, but it means marketing should never present the earlier trial as the final answer.

Why can good trials disagree?

• Dry eye is not one condition. Aqueous deficiency, MGD, allergy, neuropathic pain and environmental stress can produce overlapping symptoms.
• Controls may not be inert. Olive, safflower and grapeseed oils have different fatty acids and biological effects.
• Formulations differ. Dose, EPA percentage, rTG versus ethyl ester, vitamin D and capsule schedule vary.
• Background treatment differs. Some studies allow participants to continue other dry-eye therapies.
• Symptoms fluctuate. Weather, screens, adherence and regression to the mean can influence outcomes.
• Outcome measures disagree. Symptoms and clinical signs often correlate poorly in dry eye.

Why is PRN De3 still a leading option?

If a Canadian adult and their eye-care professional decide an omega-3 use is advisable, PRN De3 offers unusually clear specifications: 2,240 mg EPA+DHA, a 3:1 EPA:DHA ratio, rTG form, vitamin D3, third-party quality positioning and an active Health Canada licence with MGD-related dry-eye claims.

That makes it a strong, rational, evidence-informed choice among supplements. Read how its formula compares with I-VU, NutraSea, Systane and Blink.

How should you judge your own trial?

Agree on a defined window—often 90 days—and keep other major variables as stable as practical. Track symptoms and function rather than waiting for a vague feeling: burning, grittiness, comfortable screen time, contact-lens tolerance, morning comfort and frequency of rescue drops. An eye-care professional can repeat tear break-up time, osmolarity, staining or gland assessment when appropriate.

If there is no meaningful improvement, revisit the diagnosis and the rest of the treatment plan. See how to structure a PRN De3 90-day trial.

Frequently asked questions

Was PRN De3 clinically studied?

Yes. Its 1,680 mg EPA/560 mg DHA rTG formula has been used in randomized trials, including both a positive 2016 study and a negative 2024 study.

Does DREAM prove all omega-3s fail?

No. It found no benefit for its tested ethyl-ester regimen over olive oil in its population. It is strong evidence against universal claims, not proof that every formula fails every subgroup.

Can Health Canada authorize claims when studies are mixed?

Yes. A product licence reflects evidence reviewed for specific conditions of use. It does not mean every future trial will be positive or that the result is guaranteed.

Sources

• Epitropoulos et al., 2016
• DREAM Research Group, 2018
• Randomized De3 MGD trial, 2024
• Cochrane review, 2019
• Wang and Ko meta-analysis, 2023
• Health Canada NPN 80101489

This evidence summary is educational and does not provide individual medical advice.

A premium formula can only be evaluated if the routine is consistent. PRN De3 supplies its stated 1,680 mg EPA, 560 mg DHA and 1,000 IU vitamin D3 at the full three-softgel daily serving.

What is the recommended dose?

Health Canada's licence lists three capsules once daily for adults 19 and older. The EyeDropShop product is available in 90, 180 and 270 softgels, corresponding to approximately 30, 60 and 90 days at the labelled dose.

Should you take all three together?

The Canadian direction is three once daily. Taking them with a meal is practical because dietary fat supports digestion of fat-soluble nutrients and often improves fish-oil tolerability. Choose a meal you eat reliably.

If three capsules at once cause reflux or nausea, ask a pharmacist or clinician whether splitting the dose is appropriate. Do not improvise a permanently lower dose and assume you are receiving the studied formula.

Why use a 90-day trial?

Oral omega-3 does not work like a drop. Incorporation into blood lipids and tissues takes time, and dry-eye trials commonly run for 8 to 12 weeks or longer. PRN currently advises allowing at least 90 days, although some users may notice a change sooner.

A structured trial should have a start date, consistent dose, stable background routine and a review date. Record a weekly 0–10 score for burning, grittiness, end-of-day comfort, screen tolerance and rescue-drop frequency. If possible, pair symptom tracking with an eye-care follow-up.

What side effects can occur?

Fish-oil supplements may cause fishy aftertaste, burping, reflux, nausea, loose stool or abdominal discomfort. Taking capsules with a meal, storing them as directed and avoiding bedtime dosing may help. Stop and seek advice for allergic symptoms or unusual bleeding.

The Canadian product contains fish oil, bovine gelatin and soy-derived mixed tocopherols. Read the current package if you have food allergies or dietary restrictions.

Who should check before starting?

• People taking anticoagulants, antiplatelet drugs or other medicines affecting bleeding.
• People with a bleeding disorder or upcoming surgery/dental procedure.
• Anyone with fish, seafood, soy or capsule-ingredient allergy.
• People who are pregnant or breastfeeding.
• People taking vitamin D, calcium or multiple eye-health supplements.
• Those with kidney disease, high calcium or another condition affected by vitamin D.
• Anyone under 19, because the licensed dose is for adults.

Can you take PRN De3 with dry-eye drops?

Omega-3 and lubricating drops work in different ways and are often used in the same overall plan. PRN De3 does not replace preservative-free tears, warm compresses, lid hygiene, environmental changes or prescription treatment when those are indicated.

Dry eye has many causes. If symptoms are primarily allergic, medication-related, aqueous-deficient or neuropathic, omega-3 alone may not address the main driver.

When should you stop the trial?

Stop and obtain advice for a suspected allergy, significant gastrointestinal effects, easy bruising or bleeding, or a new medication interaction. If there is no meaningful eye benefit after a consistent 90-day trial, review the plan rather than continuing indefinitely by habit.

Seek prompt eye care for pain, sudden vision change, injury, discharge, marked light sensitivity or one-sided severe redness. A supplement is not an emergency treatment.

How do you avoid double-counting vitamin D?

PRN De3 supplies 1,000 IU (25 mcg) daily. Add vitamin D from multivitamins, standalone D3, calcium combinations and other eye formulas. Your clinician can advise whether the total fits your needs and whether testing is appropriate.

A simple 90-day checklist

1. Confirm suitability with a pharmacist or clinician.
2. Record baseline symptoms and current treatments.
3. Take three softgels daily with the same meal.
4. Keep other major treatment changes to a minimum unless medically necessary.
5. Track weekly comfort and functional measures.
6. Review at 12 weeks: better, unchanged or worse?
7. Continue only if benefit, tolerability, cost and professional advice support it.

Frequently asked questions

Can I take one softgel three times daily?

The licence says three capsules once daily. Ask your eye care practitioner before changing the schedule for tolerability.

What if I miss a day?

Resume the regular labelled schedule. Do not double the next dose unless a healthcare professional instructs you.

Should it be refrigerated?

Follow the storage directions on the current Canadian bottle. Keep it sealed, away from heat, light and children's reach.

Can I judge it after one bottle?

A 90-count bottle lasts about 30 days, which may be too short for a fair trial. The brand recommends about 90 days.

Sources

• Health Canada NPN 80101489
• EyeDropShop Canada product page
• EyePromise De3 directions

This article provides general education, not individualized medical or pharmaceutical advice.

Comparing supplements by bottle size or “1,000 mg fish oil” can be misleading. The meaningful figures are the full daily EPA and DHA dose, oil form, added nutrients, number of capsules and authorized use.

The table below uses current Canadian EyeDropShop product information. Formulas can change, so confirm the label before purchasing.

Why PRN De3 earns the “top dry-eye omega” position

PRN De3 is not the winner of every possible category. It is the strongest all-around omega-3 choice in this group when the decision is based on a combination of high EPA+DHA dose, rTG form, dry-eye-specific clinical history, vitamin D3 and Health Canada-authorized MGD-related claims.

Its 1,680 mg EPA is higher than the compared omega products, and its combined 2,240 mg EPA+DHA is also the highest. The formula matches the dose used in published randomized dry-eye studies. These are substantive differences, not simply brand prestige.

PRN De3 vs I-VU Omega-3 Plus

Both use re-esterified triglyceride omega-3, which makes this the closest format comparison. I-VU provides 1,200 mg EPA, 600 mg DHA and 24 mg DPA in two capsules. PRN provides 480 mg more EPA, 40 mg less DHA and adds 1,000 IU vitamin D3 in three capsules.

Choose the conversation based on priorities. PRN has the larger EPA+DHA dose, the 3:1 profile and more directly product-matched dry-eye evidence. I-VU has a simpler two-capsule routine, includes DPA and may appeal to someone who already receives enough vitamin D elsewhere.

PRN De3 vs NutraSea Dry Eye

NutraSea uses triglyceride-form omega-3 with 1,200 mg EPA, 300 mg DHA and 150 mg GLA from evening primrose/borage sources. Its 4:1 EPA:DHA ratio is even more EPA-dominant than PRN, but the total EPA+DHA dose is lower and the serving is four softgels.

GLA makes NutraSea a different strategy, not a weaker copy. Someone seeking an omega-3-plus-GLA formula may prefer it. PRN remains the more concentrated EPA+DHA choice and includes D3 rather than GLA.

PRN De3 vs Systane Omega-3

Systane provides 400 mg EPA and 200 mg DHA per softgel, taken three times daily: 1,200 mg EPA plus 600 mg DHA. It uses triglyceride form and has Health Canada dry-eye wording on the Canadian product description.

PRN delivers 440 mg more combined EPA+DHA per day, uses rTG, has a higher EPA percentage and includes D3. Systane offers a clean two-ingredient marine-oil approach without added D3.

PRN De3 vs Blink NutriTears

Blink NutriTears is not an omega-3 competitor in the literal sense. Its one-softgel formula lists vitamin D, lutein, zeaxanthin and curcuminoids, but no EPA or DHA. It targets dry-eye nutrition through a different ingredient set and dramatically lower capsule burden.

For a shopper specifically seeking high-dose EPA/DHA, PRN is the clear fit. For someone unable or unwilling to take fish oil, Blink is a separate category worth discussing. Fish allergy still requires professional guidance; “fish-free” should be verified on the current label.

What about generic fish oil?

A generic can be high quality, but compare active ingredients. A label that says “1,000 mg fish oil” may provide only about 300 mg EPA+DHA. Matching PRN's 2,240 mg could require many capsules. Also check whether the oil is triglyceride, rTG or ethyl ester and whether independent purity data are available.

Price per bottle is therefore less informative than price per 1,000 mg EPA+DHA at the intended daily serving. Even then, a cheaper equivalent should match form, tolerability and quality—not just milligrams.

Which product is right for which priority?

• Highest combined EPA+DHA plus D3: PRN De3.
• Two-capsule rTG formula: I-VU Omega-3 Plus.
• Omega-3 plus GLA: NutraSea Dry Eye.
• Simple triglyceride EPA/DHA formula: Systane Omega-3.
• One capsule without listed EPA/DHA: Blink NutriTears.

Frequently asked questions

Is PRN De3 worth the premium?

It offers the highest EPA+DHA dose in this comparison, rTG form, vitamin D3 and unusually specific Canadian dry-eye claims. Whether those differences justify the price depends on response, budget and professional advice.

Which has the fewest capsules?

Blink uses one daily but is not an omega-3 formula. Among compared omega products, I-VU uses two; PRN and Systane use three; NutraSea uses four.

Can I combine two products?

Do not stack them without reviewing total EPA, DHA, vitamin D and bleeding risk with a pharmacist or physician.

Sources

• Current EyeDropShop Canada product pages for PRN De3, I-VU Omega-3 Plus, NutraSea Dry Eye Soft Gels, Systane Omega-3 and Blink NutriTears, accessed July 2026.
• Health Canada NPN 80101489
• Epitropoulos et al., 2016

Product details may change. Check the current Canadian label and consult a healthcare professional.